Search Results - "Rozzo, Stephen J"

Long‐term efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 5‐year extension of a phase 3 study (reSURFACE 1) by Imafuku, Shinichi, Nakagawa, Hidemi, Igarashi, Atsuyuki, Morita, Akimichi, Okubo, Yukari, Sano, Shigetoshi, Tada, Yayoi, Nemoto, Osamu, Rozzo, Stephen J., Kawamura, Masaki, Ohtsuki, Mamitaro

“…The three part, double‐blind, randomized, controlled reSURFACE 1 trial and extension study (NCT01722331) evaluated efficacy and safety of tildrakizumab in…”
Get full text

Evidence for an Interferon-Inducible Gene, Ifi202, in the Susceptibility to Systemic Lupus by Rozzo, Stephen J, Allard, John D, Choubey, Divaker, Vyse, Timothy J, Izui, Shozo, Peltz, Gary, Kotzin, Brian L

“…The Nba2 locus is a major genetic contribution to disease susceptibility in the (NZB × NZW)F 1 mouse model of systemic lupus. We generated C57BL/6 mice…”
Get full text

Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2) by Lebwohl, Mark G., Leonardi, Craig L., Mehta, Nehal N., Gottlieb, Alice B., Mendelsohn, Alan M., Parno, Jeff, Rozzo, Stephen J., Menter, M. Alan

“…Data for the effect of metabolic syndrome (MetS) on the efficacy and safety of biologic agents for psoriasis treatment are limited. To evaluate long-term…”
Get full text

Response to: "Interleukin-23 Blockade Is Not Effective in Axial Spondyloarthritis" by Peters, Eric, Chou, Richard C, Rozzo, Stephen J, Yao, Siu-Long, García Fructuoso, Ferran José

Get full text

Tildrakizumab efficacy and safety are not altered by metabolic syndrome status in patients with psoriasis: Post hoc analysis of 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2) by Lebwohl, Mark G., Leonardi, Craig L., Mehta, Nehal N., Gottlieb, Alice B., Mendelsohn, Alan M., Parno, Jeff, Rozzo, Stephen J., Menter, Alan

Get full text

A Randomized, Double-Blind, Placebo-Controlled Phase 2a Study of Tildrakizumab Efficacy and Safety in Patients With Active Ankylosing Spondylitis by Peters, Eric, Chou, Richard C., Rozzo, Stephen J., Yao, Siu-Long, Fructuoso, Ferran José García

“…Tildrakizumab is an anti-interleukin-23p19 monoclonal antibody approved to treat moderate to severe plaque psoriasis. This study evaluated the efficacy and…”
Get full text

Effect of Genetic Background on the Contribution of New Zealand Black Loci to Autoimmune Lupus Nephritis by Rozzo, Stephen J., Vyse, Timothy J., Drake, Charles G., Kotzin, Brian L.

“…Autoimmune diseases such as systemic lupus erythematosus are complex genetic traits with contributions from major histocompatibility complex (MHC) genes and…”
Get full text

Homeostatically proliferating CD4 T cells are involved in the pathogenesis of an Omenn syndrome murine model by Khiong, Khie, Murakami, Masaaki, Kitabayashi, Chika, Ueda, Naoko, Sawa, Shin-ichiro, Sakamoto, Akemi, Kotzin, Brian L, Rozzo, Stephen J, Ishihara, Katsuhiko, Verella-Garcia, Marileila, Kappler, John, Marrack, Philippa, Hirano, Toshio

“…Patients with Omenn syndrome (OS) have hypomorphic RAG mutations and develop varying manifestations of severe combined immunodeficiency. It is not known which…”
Get full text

Control of Separate Pathogenic Autoantibody Responses Marks MHC Gene Contributions to Murine Lupus by Vyse, Timothy J., Halterman, Richard K., Rozzo, Stephen J., Izui, Shozo, Kotzin, Brian L.

“…Previous studies have suggested that MHC and non-MHC genes contribute to the development of autoimmune disease in F1 hybrids of New Zealand black (NZB) and…”
Get full text

Aging-Dependent Exclusion of Antigen-Inexperienced Cells from the Peripheral B Cell Repertoire by Johnson, Sara A, Rozzo, Stephen J, Cambier, John C

“…Aging is accompanied by greatly reduced B cell production in the bone marrow, yet peripheral B cell numbers do not decline. We hypothesize that this may…”
Get full text

Differential Role of Three Major New Zealand Black-Derived Loci Linked with Yaa-Induced Murine Lupus Nephritis by Kikuchi, Shuichi, Fossati-Jimack, Liliane, Moll, Thomas, Amano, Hirofumi, Amano, Eri, Ida, Akinori, Ibnou-Zekri, Nabila, Laporte, Catherine, Santiago-Raber, Marie-Laure, Rozzo, Stephen J, Kotzin, Brian L, Izui, Shozo

“…By assessing the development of Y-linked autoimmune acceleration (Yaa) gene-induced systemic lupus erythematosus in C57BL/6 (B6) x (New Zealand Black (NZB) x…”
Get full text

Effects of MHC and Gender on Lupus-Like Autoimmunity in Nba2 Congenic Mice by Gubbels, Melanie R, Jorgensen, Trine N, Metzger, Troy E, Menze, Katherine, Steele, Heather, Flannery, Shannon A, Rozzo, Stephen J, Kotzin, Brian L

“…The lupus-like disease that develops in hybrids of NZB and NZW mice is genetically complex, involving both MHC- and non-MHC-encoded genes. Studies in this…”
Get full text

New Loci from New Zealand Black and New Zealand White on Chromosomes 4 and 12 Contribute to Lupus-Like Disease in the Context of BALB/c by Rigby, Robert J, Rozzo, Stephen J, Boyle, Joseph J, Lewis, Margarita, Kotzin, Brian L, Vyse, Timothy J

“…New Zealand Black (NZB) and New Zealand White (NZW) mice are genetically predisposed to a lupus-like autoimmune syndrome. To further define the loci linked to…”
Get full text

42290 Patients’ quality of life in a Phase 4 real-world study of tildrakizumab in moderate-to-severe plaque psoriasis by Heim, Jayme, Vasquez, J Gabriel, Rozzo, Stephen J., Schenkel, Brad, Bhatia, Neal

Get full text

42295 Safety of tildrakizumab in a Phase 4 real-world study in patients with moderate-to-severe plaque psoriasis by Vasquez, J Gabriel, Bhatia, Neal, Schenkel, Brad, Rozzo, Stephen J., Heim, Jayme

Get full text

42293 Real-world effectiveness of tildrakizumab in a Phase 4 study in patients with moderate-to- severe plaque psoriasis by Bhatia, Neal, Vasquez, J Gabriel, Schenkel, Brad, Rozzo, Stephen J., Heim, Jayme

Get full text

42297 Insights into the efficacy and safety of tildrakizumab in patients with moderate-to-severe plaque psoriasis across age quartiles: Pooled analyses from the Phase 3 reSURFACE 1 and reSURFACE 2 trials by Elewski, Boni, Han, George, Rozzo, Stephen J., Gogineni, Ranga, Schenkel, Brad, Guenthner, Scott

Get full text

42281 Patient satisfaction with tildrakizumab treatment in a Phase 4 real-world study of tildrakizumab in patients with moderate-to-severe psoriasis by Bhatia, MD, Neal, Vasquez, J Gabriel, Schenkel, Brad, Rozzo, Stephen J., Heim, Jayme

Get full text

A Novel Locus Regulates Both Retroviral Glycoprotein 70 and Anti-Glycoprotein 70 Antibody Production in New Zealand Mice When Crossed with BALB/c by Rigby, Robert J, Rozzo, Stephen J, Gill, Herpreet, Fernandez-Hart, Timothy, Morley, Bernard J, Izui, Shozo, Kotzin, Brian L, Vyse, Timothy J

“…Lupus-prone New Zealand Black and New Zealand White mice produce high serum levels of the endogenous retroviral envelope protein gp70 and develop an Ab…”
Get full text

33133 A phase 4, real-world study of tildrakizumab in moderate to severe psoriasis: Week 28 interim analysis by Heim, Jayme, Vasquez, J. Gabriel, Beute, Paulita, Torres, Monique, Rozzo, Stephen J., Bhatia, Neal

Get full text